Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide vs Bicalutamide in Metastatic Prostate Cancer (TERRAIN)
NCT01288911Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2011
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Astellas Pharma. Started Mar 2011; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01288911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01288911.